CX30 – a new potential target

Researchers at GIGA and CHU analyzed the tumor suppressive effects of Cx30 in malignant astrocytic gliomas. They demonstrated the growth inhibitory potential in these tumors and dissected the involved signaling cascades. In addition, however, Cx30 protected human gliomas against radiation-induced DNA damage via a heat shock protein (HSP 90–dependent) translocation into the mitochondria favoring ATP production, DNA repair, and cell survival. In a clinical setting, it was shown that Cx30 expression adversely affected patient survival in 2 independent cohorts of radiation-treated glioblastoma patients.

These results demonstrate the central regulatory role of Cx30 in the biology of human gliomas. Acting as both a tumor growth suppressor and a radioprotective agent, this protein is a potential biomarker and an attractive target for specific therapeutic interventions against these tumors.

Interested in these projects? Drop us an email [info@b2h.be]. We are looking forward collaborating with you!

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials